Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer.1,2 Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.3
UVA and UVB — UV radiation is classified based on wavelength as UVB (290-320 nm), UVA2 (320-340 nm), and UVA1 (340-400 nm). UVA, which makes up 95% of...
RELEASE
Penpulimab-kcqx (Anniko – Akeso Biopharma), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin or carboplatin plus gemcitabine for first-line treatment of recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma and for use as monotherapy for metastatic disease in adults with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Penpulimab is the second immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma; toripalimab (Loqtorzi) was approved in 2024.1
STANDARD TREATMENT — Most cases of nasopharyngeal carcinoma are detected at later stages (stage III or IV) and survival rates are relatively low. The standard first-line treatment of recurrent or metastatic nasopharyngeal carcinoma is platinum-based …